

Treating to target in PsA – how routine use may impact on clinical decision making?

Dr Laura C Coates, NIHR Clinician Scientist and Senior Clinical Research Fellow, MBChB, MRCP (UK),  
PhD

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of  
Oxford, Oxford, UK.

Dr Laura C Coates

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,

Botnar Research Centre

Windmill Road

Oxford, OX2 6PX

UK.

Tel - +44 1865737545

Email – [laura.coates@ndorms.ox.ac.uk](mailto:laura.coates@ndorms.ox.ac.uk)

In recent years there has been increasing research focusing on the assessment of disease activity in psoriatic arthritis (PsA). PsA has been recognised as a potentially destructive and disabling arthritis and many observational studies have supported a link between inflammation and subsequent joint damage. The Tight Control of PsA (TICOPA) trial subsequently showed that treating to target, using the minimal disease activity (MDA) criteria improved arthritis, skin, functional and quality of life outcomes[1]. In 2015, as a result of this study, the updated EULAR recommendations for the management of PsA stated that “Treatment should be aimed at reaching the target of remission or, alternatively, minimal/low disease activity, by regular monitoring and appropriate adjustment of therapy” [2]. However this has not been widely implemented in clinical practice as yet, highlighting a delay in translating best practice from clinical trials to real-life clinical practice.

In this issue of Rheumatology, van Mens et al report the results of an observational real-life study highlighting the potential discrepancy between current routine clinical practice and a target driven assessment. They analysed patients who were felt by their physician to be in an acceptable disease state not requiring any change in treatment to establish their assessed disease activity levels. They then compared the patients who did and did not meet the minimal disease activity (MDA) criteria.

The MDA criteria for PsA are a validated measure of an acceptable disease state including measures of arthritis (68/66 joint count) skin (psoriasis area and severity index [PASI] or body surface area), enthesitis and patient reported pain, global and function[3]. Achievement of the MDA criteria has been shown to correlate well with low impact of disease reported by patients[4] and result in better functional outcome and lower radiographic damage over 1-5 years follow up[5-7].

The study recruited 250 patients from routine rheumatology clinics who were considered by their treating rheumatologist to be in an acceptable disease state. They were recruited from two hospital sites but over 30 referring clinicians to remove bias from individual physician’s assessments. These patients had to have been stable for 6 months with no treatment change (or planned treatment change) but were accepted regardless of therapy. This inclusion criteria was designed to assess current clinical practice and so did not require any additional assessments of disease activity, just the physician’s overall opinion. Unfortunately, patients not considered in acceptable disease states were not assessed so we do not know what proportion of patients they represent.

Following referral, patients underwent a full clinical assessment examining peripheral joints, skin, enthesitis, dactylitis and spinal disease as the principle domains of PsA disease. Patients also completed a wide range of questionnaires including assessments of function, quality of life, anxiety and depression and work productivity.

Unsurprisingly, the average levels of disease activity were low in-keeping with the physicians’ opinion. However, of the 250 patients reviewed, only around 2/3<sup>rd</sup> of them fulfilled MDA criteria (MDA+), whilst one third did not (MDA-). When examining why MDA was not fulfilled in these patients, it was clear that residual disease activity was significantly higher across all domains. This was not limited to measures such as pain or functional impairment, which may be related to other conditions but also to specific PsA measures such as tender/swollen joint counts, skin scores, enthesitis and dactylitis counts. The physician global VAS was also significantly higher suggesting that physicians were aware that disease was not as optimally controlled in these patients.

When examining these MDA- patients, multivariate analysis showed that they were more frequently female, older and had a higher body mass index (BMI) all of which are in-keeping with previous research. Analysis by treatment group showed no significant difference between those on NSAIDs alone (around 10% of cases), csDMARDs only (around 40% of cases) or those receiving TNF inhibitors (around 50% of cases). Of course this study only included those felt to be well controlled so this does not necessarily reflect the effectiveness of these therapies in PsA.

This study gives us the first real-life insight into the differences that may follow from implementing a treat to target strategy for PsA in routine clinical practice. Around 1/3 of these patients would have been considered for escalation of therapy if following a treat to target regime using MDA. Interestingly, it was clear in this study that doctors were aware of the higher levels of disease activity (significantly higher physician global scores median 23mm for MDA- vs 7mm for MDA+) but they did not feel that treatment should be changed. Obviously in routine practice, there may be practical reasons in individual cases why escalation of therapy may not be appropriate: comorbidities; contraindications to therapies; patient refusal; or no other treatment options available. However it seems likely that overall doctors accept a higher level of disease activity than seen in the MDA criteria.

This study also highlights the impact of that disconnect. The MDA- patients had significantly worse scores on all patient reported outcomes. Some of these (patient pain, global and HAQ) are included in the MDA criteria so it is unsurprising that these are higher. However the difference was very marked in some cases, for example functional impairment seen in 9.5% of MDA+ patients but 72% of MDA- patients. In addition to these differences, independent measures of impact including quality of life, anxiety and depression and work productivity all showed significantly higher impact on patient's lives for those who did not achieve MDA.

It is clear from this study that patients felt to be in an acceptable disease state who do not meet the MDA criteria have higher levels of disease activity and this is associated with a significant impact on their functional ability, quality of life, mental health and work productivity. Coupled with results from the TICOPA study and the assertions of the EULAR recommendations for the care of PsA, this should challenge clinicians to incorporate these simple assessments into their routine patient care and strive for better outcomes for all patients.

## References

- 1 Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet* 2015;386(10012):2489-98.
- 2 Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2016;75(3):499-510.
- 3 Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis* 2010;69(1):48-53.
- 4 Queiro R, Canete JD, Montilla C, et al. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. *Arthritis research & therapy* 2017;19(1):72.
- 5 Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. *Arthritis Care Res (Hoboken)* 2016;68(2):267-74.
- 6 Coates LC, Helliwell PS. Validation of minimal disease activity for psoriatic arthritis using interventional trial data. *Arthritis Care and Research* 2010;62(2):965-69.
- 7 Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. *Arthritis Care Res (Hoboken)* 2010;62(7):970-6.